Several incentives are being considered by the European Commission to enhance access to medicines and overcome unmet medical need (UMN), including the conditionality of regulatory data protection.
Under this system, companies would only receive their maximum duration of data protection if they meet a series of conditions – One under consideration is that companies must launch a product in all 27 EU Member States within a given timeframe – known as launch conditionality.
On our latest podcast, we break down the potential impact of the launch condition on the small and mid-sized #healthtechnology company. To help us do so, we’re joined by Thomas Bols from PTC Therapeutics, Inc., Johanna Grames from AOP Health and EUCOPE’s Alexander Natz. This episode is hosted by EUCOPE’s Government Affairs Manager Victor Maertens